Gaudium IVF FY26 net profit rises 28% to ₹24.48 crore

Gaudium IVF and Women Health Limited reported a 28% increase in consolidated net profit for the financial year ended March 31, 2026, reaching ₹24.48 crore, compared to ₹19.17 crore in the previous year. Revenue from operations for FY26 grew 48% to ₹104.35 crore from ₹70.72 crore in FY25. The company's board approved the audited standalone and consolidated financial results on May 28, 2026.

For the quarter ended March 31, 2026, the company reported a consolidated net profit of ₹8.36 crore, an increase of 29% from ₹6.45 crore in the corresponding quarter of the previous year. Revenue for the quarter stood at ₹30.35 crore, with EBITDA rising 40% year-on-year to ₹12.17 crore. The statutory auditors, S K G N & Associates LLP, issued an unmodified opinion on the financial results.

Consolidated Financial Performance

The company achieved an EBITDA margin of 40.10% in Q4FY26, compared to 32.39% in the prior year. For the full year, the EBITDA margin was 36.13%. Profit After Tax (PAT) from continuing operations for FY26 was ₹24.48 crore, with a PAT margin of 23.47%.

Particulars	Q4FY26 (₹ Cr)	Q4FY25 (₹ Cr)	YoY	FY26 (₹ Cr)	FY25 (₹ Cr)	YoY
Revenue from Operations	30.35	26.92	12.74%	104.35	70.72	47.56%
EBITDA	12.17	8.72	39.56%	37.70	28.63	31.69%
EBITDA Margin %	40.10%	32.39%	771 bps	36.13%	40.48%	(435) bps
Profit After Tax (PAT)	8.36	6.45	29.46%	24.48	19.17	27.69%
PAT Margin %	27.54%	23.98%	356 bps	23.47%	27.12%	(365) bps

Key Ratios and Cash Flows

The company's Return on Equity (RoE) average for FY26 was 24.66%, while Return on Capital Employed (RoCE) average stood at 34.80%. The Debt/Equity ratio improved to 0.16, reflecting the impact of the ₹90 crore fresh equity infusion through the IPO listed on February 27, 2026.

Ratio	FY25	FY26
EBITDA Margin	40.48%	36.13%
PAT Margin	27.12%	23.47%
Debt / Equity	0.45	0.16
RoE Average	52.34%	24.66%
RoCE Average	65.54%	34.80%

Cash flow from operating activities for FY26 was ₹724.72 lakh, while cash used in investing activities was ₹8,765.41 lakh. Net cash and cash equivalents increased by ₹157.07 lakh to close at ₹878.57 lakh.

Operational Highlights and Future Outlook

Gaudium IVF maintained a network of 7 hubs and 28 spokes in FY26, delivering a clinical pregnancy success rate of 58% on the first IVF attempt. In April 2026, the company became the first IVF chain in India to integrate AI-led embryology into routine clinical practice through a partnership with UK-headquartered IVF 2.0, deploying the SiD and ERICA platforms.

Dr. Manika Khanna, Chairperson and Managing Director, attributed the growth to higher patient volume at mature hubs and a high clinical success rate. She outlined the expansion strategy, noting that of the 19 new IVF hubs planned under the IPO use-of-proceeds, 3 are expected to be operational soon. The company plans to take the total hub count to 10 in FY27, followed by 8 in FY28 and 1 in FY29, expanding deeper into Tier-II markets.

Regulatory Disclosure

Pursuant to Regulation 30 and Regulation 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, the company has informed that the audio recording of the earnings call on the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, is available. The recording, held on Friday, May 29, 2026, has been uploaded to the company's website at https://www.gaudiumivfcentre.com/audio-player/q4-fy26 .

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.00%	-7.79%	-14.51%	+24.02%	+24.02%	+24.02%

gaudium ivf & women health has announced that the National Company Law Tribunal (NCLT), New Delhi Bench, has rejected an insolvency petition filed against it. The order was passed by the Hon'ble NCLT on May 15, 2026, in the matter of M/s. Ramaa Capital versus the company.

The petition, bearing number C.P. (IB)/243/ND/2026, was filed under Section 9 of the Insolvency and Bankruptcy Code, 2016, by the operational creditor. The company received a copy of the said order on May 22, 2026.

Details of the Order

The disclosure was made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The key details regarding the regulatory order are outlined below:

Sr. No.	Particulars	Description
1.	Name of the authority	Hon'ble National Company Law Tribunal (NCLT)
2.	Nature and details of the action(s) taken or order(s) passed	The Hon'ble NCLT, New Delhi Bench, vide order dated May 15, 2026, has rejected the Petition of the Operational Creditor.
3.	Date of receipt of direction or order	May 22, 2026
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Not Applicable
5.	Impact on financial, operation or other activities of the listed entity	There is no impact on financial, operation or other activities of the Company.

Impact Assessment

The company has confirmed that the rejection of the petition has no quantifiable monetary impact on its financial, operational, or other activities. The information has been submitted to the exchanges and is also available on the company's website.